We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Search results (195)

« Back to Publications

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.

Rampotas A. et al, (2026), Sci Transl Med, 18

The fetal specific gene LIN28B is essential for human fetal B-lymphopoiesis and initiation of KMT2A::AFF1 infant leukemia.

Ling RE. et al, (2026), Blood

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

Rampotas A. et al, (2026), Br J Haematol

Mutant calreticulin-Cancer driver and Achilles' heel for ET?

Reichert M. and Psaila B., (2026), Hemasphere, 10

comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disorders.

Shen Y. et al, (2026), Cell Stem Cell, 33, 421 - 437.e7

JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.

Kealy D. et al, (2026), Leukemia, 40, 609 - 621

Rapid and durable recovery of immune effector cells in myelofibrosis patients treated with momelotinib.

Makker J. et al, (2026), Haematologica, 111, 1096 - 1099

Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1.

Palandri F. et al, (2026), Clin Lymphoma Myeloma Leuk

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis.

O'Sullivan J. et al, (2026), Br J Haematol, 208, 437 - 441

Supp Table 7 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2025)

Figure 6 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2025)

Figure 7 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2025)

Supp Table 2 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2025)

Supp Table 3 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2025)

Figure 1 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2025)

Load More

1
2
3
4
5
6
7
...
»